- $117.09m
- $110.87m
- $58.45m
- 50
- 19
- 26
- 23
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.4 | 18.2 | 29.5 | 41.4 | 58.5 |
Cost of Revenue | |||||
Gross Profit | 9.27 | 11.2 | 18.8 | 27 | 40.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 34.6 | 43.5 | 58.9 | 81.7 | 103 |
Operating Profit | -19.2 | -25.3 | -29.5 | -40.2 | -44.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.4 | -28.8 | -33.3 | -44.3 | -46.7 |
Net Income After Taxes | -22.4 | -28.8 | -33.3 | -44.3 | -46.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -22.4 | -28.8 | -33.3 | -44.3 | -46.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.2 | -28.8 | -33.3 | -44.3 | -46.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.65 | -2.23 | -2.3 | -2.65 | -2.04 |